NEWPORT NEWS, Va.
, Aug. 15, 2012
/PRNewswire/ -- Molecular Breast Imaging (MBI), also known as Breast-Specific Gamma Imaging (BSGI), is a breast imaging procedure performed using a tracer which accumulates in cancer cells making them detectable with special imaging systems. Several studies have demonstrated its ability to detect cancers missed by mammography and ultrasound, and now researchers are performing studies at lower doses in hopes of confirming a method to reduce the overall radiation exposure to the patient. A lowered overall radiation exposure is a benefit during screening of high risk women with dense breasts.
According to a presentation at the European Society of Radiology Congress in Vienna
this spring, Dr. Marcela Bohm-Velez
of Weinstein Imaging Associates in Pittsburgh, PA
, concluded that low-dose studies are possible when conducted under a properly designed clinical protocol.
The findings were obtained from an on-going study in which additional patients have been recently added. In their prospective trial, 60 patients had low-dose MBI followed by imaging at the standard dose. To date, the study revealed that the tracer washes out of the breast cells fairly quickly with only half of the tracer remaining in the breast approximately 137 minutes after injection. According to the author, this is only one of the clinically significant observations and more are expected to be available this fall.
"Our early results indicate that low-dose MBI is feasible and doses of 10 mCi or less with the single head MBI imaging system can provide clinically useful images. However, the clinician needs to be aware of the pharmacokinetics of sestamibi, otherwise it can be challenging to implement low-dose protocols. The fairly rapid washout rate represents a potential stumbling block if the imaging is not managed properly; it is important to image very soon after injection to provide the best images," said Dr. Bohm-Velez. "These are physiologic effects that detector technologies cannot overcome. While all of the currently available MBI/BSGI machines are capable of low-dose imaging, low-dose imaging presents us with new challenges. Proper clinical protocols are needed to ensure optimal image quality and patient care."
About Dilon Diagnostics
Dilon Diagnostics®, a brand of Dilon Technologies® Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view gamma camera, optimized to perform MBI/BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering MBI/BSGI to their patients, such as Cornell University Medical Center, New York and George Washington University Medical Center, Washington, D.C. As part of Dilon's commitment to offering complete solutions, the new declipseSPECT is the first intra-operative handheld 3D image viewing and navigation solution with applications in SLNB breast, I-125 Seed Localization, SLNB Head and Neck etc. For more information on Dilon Technologies® please visit www.molecularbreastimaging.com
Media contact: Pjerin Luli
SOURCE Dilon Diagnostics